RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .
Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours.
This study was done to assess the antihypertensive efficacy of once-daily valsartan 20 mg , 80 mg , 160 mg , and 320 mg over 24 hours using ambulatory blood pressure monitoring ( ABPM ) . A total of 217 adult out patients with uncomplicated essential hypertension ( office mean sitting diastolic blood pressure [ DBP ] of > or = 95 to < or = 115 mm Hg ) participated in this multicenter , double-masked , placebo-controlled study . Patients were r and omized to receive valsartan 20 mg , 80 mg , 160 mg , 320 mg , or placebo for 8 weeks . Twenty-four-hour ABPM was done at baseline and after 8 weeks of treatment . All valsartan doses produced significant decreases in average ambulatory systolic blood pressure ( SBP ) and DBP over 24 hours compared with placebo . A trend to greater reductions compared with placebo was observed for doses of valsartan 80 mg and greater ( 80 mg , -6.61 mm Hg DBP , -11.04 mm Hg SBP ; 160 mg , -5.51 mm Hg DBP , -10.61 mm Hg SBP ; 320 mg , -8.44 mm Hg DBP , -14.34 mm Hg SBP ) compared with valsartan 20 mg ( -3.52 mm Hg DBP , -5.92 mm Hg SBP ) . Valsartan produced consistent reductions compared with placebo during both day ( > 6 AM to < or = 10 PM ) and night ( > 10 PM to < or = 6 AM ) . However , in all groups , the circadian pattern of blood pressure over 24 hours was preserved and was similar to that observed at baseline ( but shifted into the normotensive range in a parallel fashion ) . The data show that single daily doses of valsartan 80 mg and greater provide effective control of both DBP and SBP over a 24-hour period without loss of diurnal variation
RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .